Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL versus MECLAN.
DOXYCHEL vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily. For severe infections, continue 100 mg every 12 hours.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
12-22 hours (mean ~16 hours); prolonged in severe hepatic impairment (up to 30 hours).
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal (20-30%), biliary/fecal (40-60%), with significant enterohepatic circulation; nonrenal elimination accounts for about 70%.
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic